INTERLEUKIN-6 TRANS-SIGNALLING INHIBITION WITH OLAMKICEPT (sgp130Fc) IN ACTIVE IBD RESULTS IN EARLY UNIQUE MOLECULAR SIGNATURES PREDICTING CLINICAL REMISSION AND DIFFERENTIATING FROM REMISSION INDUCTION BY VEDOLIZUMAB OR INFLIXIMAB

Konrad Aden  1     Claudio Conrad  2     Joana Pimenta Bernardes  3     Florian Tran  4     Hanna Hoeper  3     Felix Sommer  5     Susanna Nikolaus     Juliane Lokau     Christoph Garbers     Stefan Rose-John     Christoph Röcken     Georg H Waetzig     Philip Rosenstiel     Stefan Schreiber    
1 IKMB + First Medical Department,Kiel,Germany
2 UKSH Kiel,Kiel,Germany
3 Institute of Clinical Molecular Biology Christian-Albrechts-University of Kiel,Kiel,Germany
4 Institute of Clinical Molecular Biology, University of Kiel,Kiel,Germany
5 Instit

Conference
UEG Week 2019

Citation
United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing